CYCN — Cyclerion Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $12.60m
- $9.36m
- $2.07m
Annual cashflow statement for Cyclerion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51.6 | -44.1 | -5.26 | -3.06 | -3.53 |
| Depreciation | |||||
| Non-Cash Items | 13.3 | 6.25 | -11.4 | 0.262 | 0.441 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.41 | -2.85 | -4.6 | -1.54 | -0.227 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -36.5 | -40.6 | -21.2 | -4.33 | -3.31 |
| Capital Expenditures | -0.007 | 0 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.46 | 0 | 10.4 | 0 | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | 1.46 | 0 | 10.4 | 0 | — |
| Financing Cash Flow Items | — | — | — | — | -0.13 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 30.8 | 0.029 | 5.02 | 0 | 3.32 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.27 | -40.6 | -5.81 | -4.34 | 0.008 |